Resultats de la cerca - Mark Ozeck

  • Mostrar 1 - 8 resultats de 8
Refinar resultats
  1. 1
    Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells

    Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells per Maria B. Grant, Roy Tarnuzzer, Sergio Caballero, Mark Ozeck, Margaret I. Davis, Polyxenie E. Spoerri, Igor Feoktistov, Italo Biaggioni, John C. Shryock, Luiz Belardinelli

    Publicat 1999
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

    PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor per Kai Wang, Qin Zhang, Danan Li, Keith A. Ching, Cathy Zhang, Xianxian Zheng, Mark Ozeck, Stephanie Shi, Xiaorong Li, Hui Wang, Paul A. Rejto, James G. Christensen, Peter Olson

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

    A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer per Maruja E. Lira, Yoon‐La Choi, Sun Min Lim, Shibing Deng, Donghui Huang, Mark Ozeck, Joungho Han, Ji Yun Jeong, Hyo Sup Shim, Byoung Chul Cho, Young Tae Kim, Myung‐Ju Ahn, Mao Mao

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

    An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 per Kenneth E. Hook, Scott J. Garza, Maruja E. Lira, Keith A. Ching, Nathan V. Lee, Joan Cao, Jing Yuan, Jingjing Ye, Mark Ozeck, Stephanie T. Shi, Xianxian Zheng, Paul A. Rejto, Julie L.C. Kan, James G. Christensen, Adam Pavlı́ček

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

    Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models per Cathy C. Zhang, Adam Pavlı́ček, Qin Zhang, Maruja E. Lira, Cory L. Painter, Zhengming Yan, Xianxian Zheng, Nathan V. Lee, Mark Ozeck, Ming Qiu, Qing Zong, Patrick B. Lappin, Anthony Wong, Paul A. Rejto, Tod Smeal, James G. Christensen

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

    HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib per Douglas D. Fang, Bin Zhang, Qingyang Gu, Maruja E. Lira, Qiang Xu, Hongye Sun, Maoxiang Qian, Weiqi Sheng, Mark Ozeck, Zhenxiong Wang, Cathy Zhang, Xinsheng Chen, Kevin X. Chen, Jian Li, Shu‐Hui Chen, James G. Christensen, Mao Mao, Chi-Chung Chan

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

    A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma per Cristina Papayannidis, Daniel J. DeAngelo, Wendy Stock, Bo Huang, M. Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds, Patricia A. English, Mark Ozeck, Jon C. Aster, Frank C. Kuo, Donghui Huang, Paul D. Lira, Karen R. McLachlan, Kenneth A. Kern, Guillermo Garcia‐Manero, Giovanni Martinelli

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  8. 8
    A<i>NOTCH1</i>gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

    A<i>NOTCH1</i>gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer per John J. Arcaroli, Wan‐Tien Tai, Ryan McWilliams, Stacey M. Bagby, Patrick J. Blatchford, Marileila Varella‐Garcia, Alicia Purkey, Kevin S. Quackenbush, Eun‐Kee Song, Todd M. Pitts, Dexiang Gao, Chris Lieu, Martine C. McManus, Aik Choon Tan, Xianxian Zheng, Qin Zhang, Mark Ozeck, Peter Olson, Zhi-Qin Jiang, Scott Kopetz, Antonio Jimeno, Stephen B. Keysar, Gail Eckhardt, Wells A. Messersmith

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: